A leucemia linfóide aguda (LLA) é considerada uma doença grave dos glóbulos brancos, sendo mais comum e mais agressiva em crianças e adolescentes. O tratamento para a LLA tem avançado devido aos estudos para a otimização de drogas já utilizadas em quimioterapias. Entre essas drogas estão as enzimas L- asparaginases (ASPases) que atuam reduzindo a concentração de L-asparagina (Asn) na corrente sanguínea, impedindo a proliferação das células cancerosas, visto que essas não conseguem sintetizar quantidades apropriadas desse aminoácido. No entanto, o medicamento por ser oriundo de um procarioto causa severas reações alérgicas aos usuário, afim de diminuir a imunogenicidade deste quimioterápico, é importante gerar um biofármaco oriundo de um eucarioto. Neste âmbito, obtivemos a Pichia pastoris recombinante responsável pela produção da enzima ASPase intermembranar, oriunda do gene ASP3 de Saccharomyces cerevisiae. Através do planejamento experimental, foi possível ter um aumento de 5 vezes na atividade obtida na condição inicial. O clone Mut+ alcançou sua melhor atividade de 8,6 U/g de célula nas seguintes condições: 20°C, pH inicial 6 e 1,5% de concentração de indutor. / Acute lymphoblastic leukemia (ALL) is considered a serious disease of white blood cells, is more common and more aggressive in children and adolescents. Treatment for ALL has advanced due to studies for drug optimization already used in chemotherapy. Among these drugs are the enzymes L-asparaginases (ASPases) which act by reducing the concentration of L-asparagine (Asn) in the bloodstream, preventing the proliferation of cancer cells, since these can not synthesize appropriate amounts of this amino acid. However, the drug to be derived from a prokaryote causes severe allergic reactions to the user, in order to decrease the immunogenicity of the chemotherapy, it is important to generate a biopharmaceutical derived from a eukaryote. In this context, we obtained the recombinant Pichia pastoris responsible for producing the enzyme ASPase intermembrane, coming from the ASP3 gene of Saccharomyces cerevisiae. Through the experimental design, it was possible to have a 5-fold increase in activity obtained at the initial condition. The Mut + clone achieved their best activity of 8.6 U/g cell under the following conditions: 20 °C, initial pH 6 and 1.5% of inducer concentration.

Utilizada amplamente como agente terapêutico no tratamento da leucemia linfoblástica aguda (LLA), a L-Asparaginase II (ASNase) é uma enzima que atua diminuindo a concentração de asparagina livre no plasma. Dessa forma, impede o fornecimento de asparagina para a proliferação de células malignas, as quais ao contrário das células saudáveis, não conseguem sintetizar a asparagina. A ASNase utilizada atualmente no Brasil é importada, o que gera problemas com custo e abastecimento. Sendo assim, é notavelmente atrativa a procura por sistemas que apresentem níveis elevados de expressão de asparaginase e o encontro de formas de produzir tal enzima para um fácil acesso e, se possível, com menor potencial alérgico. Isso nos incentiva a estudar a produção biotecnológica de ASNase produzida em Escherichia coli BL21 (DE3) recombinante que super expressa esta enzima. O objetivo deste trabalho foi estabelecer, em agitador orbital e sistema descontínuo, os parâmetros do cultivo e indução da bactéria Escherichia coli BL21 visando à produção de ASNase, os quais serão úteis para futuros estudos em sistema descontínuo-alimentado. Nosso trabalho avaliou fatores que influenciam a fase de crescimento e/ou a fase de indução da E. coli BL21 (DE3): meio de cultivo baseado na composição elementar, controle do pH, uso de glicose ou glicerol como fonte de carbono, formação de acetato, tempo inicial e final da indução, permeabilização celular para secreção da ASNase, concentração de indutor, temperatura de pós-indução. Nós apresentamos uma estratégia para produção extracelular de ASNase em E. coli BL21 (DE3) pelo crescimento em meio Luria Bertani (LB) modificado para permeabilização celular. A produtividade volumétrica de ASNase extracelular foi 484 IU L h-1 em agitador orbital, correspondendo a 89 % de secreção após 24h de pós-indução com IPTG a 37 ºC. Isto representou rendimento 50 % maior para a ASNase total e 15,5 vezes mais secreção de ASNase em relação ao uso do meio LB modificado. Entretanto no cultivo em biorreator de 3 L nas mesmas condições (exceto a forma de aeração: 500 rpm de agitação e 1 vvm de vazão de ar, kLa = 88 h-1) operado em regime descontínuo foram obtidos resultados semelhantes aos cultivos em agitador orbital, sendo a produtividade volumétrica da ASNase extracelular igual a 525 IU L h-1 após 20 h de pós-indução. A biomassa obtida para agitador orbital e biorreator foi 3,26 e 2,63 g L-1, respetivamente. Por esse motivo, esses resultados foram considerados promissores para aumentar a produtividade nos futuros ensaios em biorreator operado em regime descontinuo-alimentado. / Widely used as a therapeutic agent in the treatment of acute lymphoblastic leukemia (ALL), L-Asparaginase II (ASNase) is an enzyme that works by reducing the concentration of free asparagine in plasma. Thus, it prevents the delivery of asparagine to the proliferation of malignant cells, which unlike healthy cell, cannot synthesize asparagine. ASNase currently used in Brazil is imported, which causes problems with cost and supply. Thus, the search for systems with high levels of asparaginase expression and the finding of ways to produce this enzyme for easy access and, if possible, with a lower allergic potential, are strikingly attractive. This encourages us to study the biotechnological production of ASNase in recombinant Escherichia coli BL21 (DE3) which super expresses this enzyme. The objective of this work was to establish, in shaker and batch bioreactor system, growth and induction parameters of the Escherichia coli BL21 aiming the production of ASNase, which will be useful for future studies in a fed-batch system. Our work evaluated factors that influenced the growth and induction phase of E. coli BL21 (DE3): culture medium based on elemental composition, pH control, use of glucose or glycerol as carbon source, formation of acetate, initial and final induction time, cellular permeabilization for ASNase secretion, inducer concentration, post-induction temperature. We performed a strategy for extracellular production of ASNase in E. coli BL21 (DE3) by growing in modified Luria Bertani (LB) medium for cell permeabilization. The volumetric productivity of extracellular ASNase was 484 IU L h-1 on shaker, which reached 89% secretion at 24 h of post-induction with IPTG at 37°C. This represented an increase yield of 50 % regarding to the total ASNase formed and 15.5 times the ASNase secretion as compared to that attained with LB modified. While in batch 2L-bioreactor cultivation under the same conditions (except for the aeration employed: 500 rpm of stirring and 1 vvm of air flow, kLa = 88 h-1) it was obtained similar results in relation to shaker cultures. The volumetric productivity of extracellular ASNase was 525 IU L h-1 at 20 h of post-induction. The biomass obtained for shaker and bioreactor were 3.26 and 2.63 g L-1, respectively. For this reason, we consider these promising results to increase productivity in future studies in bioreactor operated as fed-batch regimen.

Submitted by Verena Bastos (verena@uefs.br) on 2015-09-21T13:18:11Z No. of bitstreams: 1 DISSERTACAO FINAL ALINE THOMAZ.pdf: 1680438 bytes, checksum: 85bf2d7886a394df745618b6fd50d435 (MD5) / Made available in DSpace on 2015-09-21T13:18:11Z (GMT). No. of bitstreams: 1 DISSERTACAO FINAL ALINE THOMAZ.pdf: 1680438 bytes, checksum: 85bf2d7886a394df745618b6fd50d435 (MD5) Previous issue date: 2015-09-27 / Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior - CAPES / The vitamin D receptor (VDR) is a cytoplasmic transcription factor and when activated by its ligand, translocates to the nucleus and interacts with DNA in the promoter regions with which has affinity, acting as a modulator of gene transcription and thereby producing multiple biological effects. Its main activities are the regulation and maintenance of plasma levels of calcium and phosphorus, as well as presenting immunomodulatory activities, such as the suppression of T cell activation, formation of secretion patterns of cytokines, modulation of proliferation and interference in the apoptosis. So this receptor is an important target for drugs that can help in the discovery of new immunomodulators. The present work had the objective to produce the recombinant vitamin D receptor in its soluble form for conducting future assays of drug screening of potential immunomodulators and drug-receptor interaction studies. For this, we used initially Escherichia coli expression system transformed with the plasmid HS_VDR_EC1-PQE T7, but it was only possible to obtain the protein in the insoluble fraction, even varying the temperature, time of induction and IPTG concentration. In an attempt to obtain soluble VDR, we used a eukaryotic expression system in insect cells using the baculovirus as a vector. It was built a vector, pFASTBacHT_VDR, which had the sequence of this protein cloned from pCMX.VDR. From there, it was possible to obtain recombinant bacmids used in transfection of insect cells, generating recombinant baculovirus, to then proceed with the expression of VDR. / O receptor de vitamina D (VDR) ? um fator de transcri??o g?nica citoplasm?tico e, quando ativado pelo seu ligante, transloca-se para o n?cleo e interage com regi?es promotoras no DNA com a qual apresenta afinidade, atuando como fator modulador da transcri??o g?nica e assim produzindo m?ltiplos efeitos biol?gicos. Suas principais atividades s?o a regula??o e a manuten??o dos n?veis plasm?ticos de c?lcio e f?sforo, e apresenta atividades imunomoduladoras, como a supress?o da ativa??o de c?lulas T, forma??o de padr?es de secre??o de citocinas, a modula??o da prolifera??o e interfer?ncia na apoptose. Sendo assim, esse receptor representa um importante alvo de drogas que pode contribuir na descoberta de novos f?rmacos com a??o imunomoduladora. O presente trabalho teve, como objetivo, produzir o VDR recombinante na forma sol?vel para a realiza??o de futuros ensaios de triagem de potenciais drogas com a??o imunomoduladora e estudos de intera??o droga-receptor. Para isso, foi utilizado, inicialmente, o sistema de express?o em Escherichia coli, utilizando o plasm?deo HS_VDR_EC1-PQE T7, por?m s? foi poss?vel obter a prote?na na fra??o insol?vel, mesmo variando a temperatura, o tempo de indu??o e a concentra??o de IPTG. Na tentativa de obter o VDR sol?vel, foi utilizado um sistema de express?o eucari?tico em c?lulas de inseto, utilizando como vetor o baculov?rus. Foi constru?do um vetor pFASTBacHT_VDR, o qual teve a sequ?ncia desta prote?na clonada a partir do pCMX.VDR. A partir da?, foi poss?vel obter bacm?deos recombinantes, utilizados na transfec??o de c?lulas de inseto, gerando baculov?rus recombinantes, para, ent?o, seguir com a express?o do VDR.

A biotecnologia é definida como qualquer aplicação tecnológica que utilize sistemas biológicos, organismos vivos, ou seus derivados, para fabricar ou modificar produtos ou processos para alguma utilização específica (ORGANIZAÇÃO DAS NAÇÕES UNIDAS, 1992). Os produtos biotecnológicos devem atender certas especificações exigidas pela Agência Nacional de Vigilância Sanitária (ANVISA), Food and Drug Administration (FDA), European Medicine Agency (EMEA) e Wood Health Organization (WHO). Para isso, utilizam-se técnicas rotineiras aplicadas à pesquisa e análise de biomoléculas como Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE), Western blot, Enzyme-Linked Immunosorbent Assay (ELISA) e espectrometria de massas (MS). A abordagem do Monitoramento de Reações Múltiplas (MRM) é considerada uma interessante alternativa aos ensaios imunoenzimáticos para caracterização e quantificação total de proteínas terapêuticas, sejam elas recombinantes ou não (KIM e DOYLE, 2010). Esta abordagem é baseada nos fundamentos da proteômica quantitativa pela utilização da cromatografia líquida acoplada à espectrometria de massas sequencial (LCMS/MS) cuja plataforma apresenta alta especificidade, sensibilidade e reprodutibilidade quantitativa em suas análises para detecção simultânea de várias regiões da estrutura proteica. Em vista disso, estabeleceu-se uma metodologia para quantificação do FVIII recombinante (FVIIIr) produzido pela linhagem celular humana Sk-Hep-1 ou do FVIII derivado do plasma (FVIIIdp), ambos utilizados no tratamento da Hemofilia A (HEMA). Para o estabelecimento da metodologia, toda uma estratégia de seleção e síntese química de peptídeos representativos das cadeias pesada e leve do FVIII humano foi empregada. Tais peptídeos obtidos foram utilizados como padrões das análises. Além disso, foi demonstrada a relação direta entre a quantificação total do FVIII com técnicas convencionais como ELISA, possibilitando a aplicação rotineira dessa abordagem para quantificação do FVIIIr e do FVIIIdp. / Biotechnology is defined as any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for a specific use (ORGANIZAÇÃO DAS NAÇÕES UNIDAS, 1992). Biotechnological products must meet certain specifications required by Agência Nacional de Vigilância Sanitária (ANVISA), Food and Drug Administration (FDA), European Medicine Agency (EMEA), and Wood Health Organization (WHO). For that routine techniques applied to research and analysis of biomolecules such Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE), Western blot, Enzyme-Linked Immunosorbent Assay (ELISA), and mass spectrometry (MS) are utilized as quality control techniques. The MS-based approach termed Multiple Reaction Monitoring (MRM) is considered an interesting alternative to immunoassays for the total quantification and characterization of therapeutic proteins, whether recombinant or not (KIM e DOYLE, 2010). This approach is based on the fundamentals of quantitative proteomics and uses of liquid chromatography coupled to tandem spectrometric mass (LC-MS/MS) to obtain a highly specific, sensitive and reproducible analysis for quantification of multiple regions of a given protein structure. Here, we established a methodology for total quantification of recombinant FVIII (rFVIII) produced in Sk-Hep-1 human cell line or of plasma derived FVIII (pdFVIII), both used in the treatment of Hemophilia A (HEMA). For that, we adopted a strategy of selection and chemical peptide synthesis of representative peptides of the heavy and light chains of human FVIII, which were used as standards in the analysis. The quantitative MRM method developed here indicated a direct correlation with FVIII quantitative techniques such ELISA, which allows routine application of such approach for rFVIII and pdFVIII quantification.

The wide diversity of plant secondary products results from different modifications undergone during biosynthesis, including glucosylation. These modification reactions result in production of the compounds actually found in plants and to unique chemical and biochemical properties, including some bitter compounds in grapefruit. While the presence of a PSPG box motif allows for identification of a clone as a putative glucosyltransferase (PGT), diversity of GT primary structures makes it difficult to accurately assign specific function. Our approach is to identify and isolate putative GT clones, express them heterologously, and biochemically characterize the proteins. Eleven putative GT clones have been isolated from Citrus paradise and some have been biochemically characterized. The current hypothesis being tested is that PGT3 and PGT9 clones are plant secondary product GTs. Due to issues with inclusion bodies when using E. coli, proteins were expressed in Pichia pastoris using the pPICZA vector. Recombinant protein expression was confirmed by Western blot and proteins were enriched by IMAC. Over 30 flavonoid and simple phenolic substrates, representing many compounds found in grapefruit, were screened for activity with PGT3 and PGT9 proteins. No significant activity was found and the biochemical function of the proteins encoded by these clones will be further investigated.

Thesis (M.Sc. (Microbiology)) --University of Limpopo, 2011 / Pterocarpus angolensis seed lectin (PAL), a 28 kDa non glycosylated protein, was initially successfully cloned and expressed in E. coli for ease of high protein production. It was discovered, however, as in similar studies that the recombinant PAL yield in E. coli is low and localized intracellularly. This makes extraction even more difficult because most of the protein is lost either when the cell undergoes lysing or when there is incomplete extraction. As a result of the low yields in E. coli, expression vectors were constructed for pal expression in S. cerevisiae, Y. lipolytica and A. niger. Colony PCR of S. cerevisiae transformants confirmed the presence of pal gene whilst sequencing revealed a 66% homology to native PAL. Expression of recombinant PAL in S. cerevisiae, which was expected to be intracellular, was doubtfully unsuccessful since no signal was detected following Western blot analysis. A pBARMTE1-pal expression vector was successfully constructed and could be used for expression studies in Aspergillus niger, however, it was not used in this study. A pal gene whose codons were optimized for Y. lipolytica was synthesized and successfully cloned and expressed in Y. lipolytica. Gene sequence alignment of native pal and the codon optimized pal showed 81% homology whilst the amino acid alignment showed 100% homology. A 31 kDa, recombinant PAL was successfully expressed in Y. lipolytica. The recombinant PAL was approximately 3 kDa larger than native PAL. It was established that this is due to glycosylation of the recombinant PAL. This recombinant protein was found to be more thermostable than native PAL since it demonstrated haemagglutination activity after 10 minutes of exposure in a boiling water bath and only lost activity after 2 hours of exposure to boiling. This study succeeded in producing a more stable extracellular recombinant PAL which demonstrated biochemical activity that was largely similar to that of native PAL but only differed in carbohydrate specificity and haemagglutinating strengths. / Flemish Interuniversity Council (VLIR-UOS)-Own Initiative Project,the SARBIO- South African Regional Co-operation in Biochemistry, Molecular Biology and Biotechnology, the (CSIR) Council for Scientific and Industrial Research,the (NRF) National Research Foundation,(TBI) The Biovac Institute Foundation, and the (SIDA) Swedish International Agency

Protéines difficiles à exprimer: un goulot d'étranglement pour la plupart des biologistes. J'ai choisi d'utiliser comme modèle d’étude Acanthamoeba polyphaga Mimivirus. Ce virus géant à ADN possède des protéines subissant des modifications post-traductionnelles, des structures multi-protéiques ou encore des voies enzymatiques jamais identifiées auparavant dans un virus, ce qui en font un modèle idéal pour l’étude de protéines récalcitrantes. Le but ultime de cette thèse, était de produire les protéines de capsides de Mimivirus. Le rôle de la protéine de capside dans l’assemblage de la particule virale, son infectivité et ses caractéristiques moléculaires sont d’une grande importance. Pour aller du gène à la protéine, J’ai participé à la compréhension de ce qui gouverne la terminaison de la transcription de Mimivirus et également participé à l'analyse globale du transcriptome au cours du cycle d'infection des amibes par Mimivirus. Nous avons montré que les transcrits de Mimivirus sont systématiquement polyadénylés dans des régions formant une structure secondaire en tige-boucle, même s’il n’existe pas de signal de polyadénylation canonique en amont. Nous en avons conclu que la polyadénylation de Mimivirus suit exclusivement une règle «épingle à cheveux». De plus, l’étude du transcriptome a révélé 3 phases temporelles distinctes dans le cycle infectieux: précoce, intermédiaire et tardive. Les transcrits de capsides sont tous exprimés durant la phase tardive mais leur profil d’expression ne sont pas superposables dans le temps. Les données de transcriptomique ont révélées la présence de plusieurs glycosyltransférases chez Mimivirus, dans la phase tardive du cycle, concomitant avec la production de la protéine de capside. Les informations recueillies sur l'expression des gènes à différents temps post-infection ont contribué à la conception de protocoles pour la production des protéines de capsides (la protéine majeure de capside (MCP) et ses paralogues) dans de systèmes eucaryote. / Difficult to express proteins: a bottleneck for most biologists. I have chosen to use Acanthamoeba polyphaga Mimivirus as my study model. This giant dsDNA virus possesses post-translationally modified proteins, multi-protein structures and enzyme pathways never before seen in a virus, which makes it ideal for refractory studies. The ultimate goal of my thesis was to produce the capsid proteins of Mimivirus. The role of the capsid protein in the assembly of the viral particle, its infectivity, and molecular features are of great importance. To go from gene to protein, I participated in the comprehension of what governs the post-transcriptional termination in Mimivirus and equally participated in the global analysis of the transcriptome during the infectious cycle of Acanthamoeba by Mimivirus. We have shown that the Mimivirus transcripts are systematically polyadenylated in the regions forming a stem-loop secondary structure; even when a canonical poyadenylation signal is absent We concluded that Mimivirus polyadenylation obeys a strict “Hairpin rule”. Moreover, the transcriptomic study revealed three distinct temporal phases: early, intermediate and late. The capsid transcripts are all expressed during the late phase but their expression profiles are not superimposable. The transcriptomic data also revealed the presence of several Mimivirus glycosyltransferases in the late temporal phase, concomitant with the capsid proteins. The expression data gathered throughout my thesis has contributed to the rational design of a protein production experiment to produce the major capsid protein and its three paralogs in eukaryotic systems.

O câncer cervical é um dos tipos de câncer mais comuns entre as mulheres, e a infecção persistente pelos HPV-16 e HPV-18 é responsável por 70% dos casos. As vacinas profiláticas disponíveis possuem alta eficácia na prevenção da infecção pelos tipos mais prevalentes de HPV. No entanto, este tipo de abordagem não beneficia mulheres que já apresentam lesões precursoras ou tumores cervicais avançados, e a busca por abordagens terapêuticas para esse tipo de câncer é considerada uma necessidade. A qualidade do antígeno representa um aspecto fundamental para o sucesso de vacinas terapêuticas baseadas em proteínas recombinantes. Neste sentido, os sistemas de expressão em células eucarióticas, como leveduras e células de mamíferos são considerados adequados para a produção de proteínas com aplicação biotecnológica. O objetivo principal deste trabalho contemplou a expressão das proteínas de fusão gDE7E6 do HPV-16 e do HPV-18 e a oncoproteína E7 do HPV-16 em células da levedura Pichia pastoris e expressão da gDE7E6 do HPV-16 e do HPV-18 em células de mamífero HEK293T e CHODG-44 para obtenção de antígenos purificados com futura aplicação em vacinas terapêuticas contra tumores associados ao HPV-16 e HPV-18. Os genes que codificam as proteínas gDE7E6 dos HPV-16 e HPV-18 e da E7 do HPV-16 foram clonados no vetor pPIC9K, os quais foram linearizados por digestão enzimática e utilizados na transformação da P. pastoris. A expressão das proteínas foi analisada nos tempos de 24, 48, 72 e 96 horas, no entanto, não foi observada a produção das proteínas no sobrenadante e nem no lisado celular. Diante desta constatação, iniciamos a expressão das proteínas gDE7E6 do HPV-16 e gDE7E6 do HPV-18 em células de mamíferos HEK293T e CHODG-44. As sequências genéticas das proteínas gDE7E6 do HPV-16 e do HPV-18 foram clonadas no vetor de expressão pNU1 e analisadas por digestão enzimática. Análises de SDS-PAGE e western blot demonstraram a expressão das proteínas gDE7E6 do HPV-16 e do HPV-18 em até 96 horas em células HEK293T. Em paralelo, realizamos a transfecção estável dos plasmídeos contendo as sequencias da gDE7E6 do HPV-16 e gDE7E6 do HPV-18 em células CHO-DG44. Com o intuito de aumentar a expressão das proteínas de interesse na população mista de CHODG-44, realizamos amplificação genômica com metotrexato (MTX), sendo possível observar aumento da expressão das proteínas, conforme aumento gradativo nas concentrações de MTX. Posteriormente, foram feitas tentativas para isolar um clone produtor das proteínas gDE7E6 HPV-16 e HPV-18, através de clonagem por diluição limitante e sistema automatizado, sendo possível isolar um clone para cada construção através de matriz semisólida, confirmado por western blot e citometria de fluxo. Apesar de demonstrar a expressão das proteínas de interesse em sistema de expressão baseado em células de mamífero, o rendimento obtido após a purificação por afinidade ao níquel foi extremamente baixo, o que dificulta a obtenção dos antígenos para fins vacinais. / Cervical cancer is one of the most common cancers among women, and persistent infection with HPV-16 and HPV-18 accounts for 70% of the cases. Available prophylactic vaccines are highly effective in preventing infection by the most prevalent types of HPV. However, this type of approach does not benefit women who already have precursor lesions or advanced cervical tumors, and the search for therapeutic approaches to this type of cancer is considered a necessity. Antigen quality represents a key aspect for the success of therapeutic vaccines based on recombinant proteins. In this sense, expression systems based in eukaryotic cells such as yeast and mammalian cells are considered suitable for the production of proteins with biotechnological applications. The main objective of this work was to express the gDE7E6 fusion proteins HPV-16 and HPV-18 and the E7 oncoprotein HPV-16 in Pichia pastoris and expression of gDE7E6 HPV-16 and HPV-18 in mammalian cells HEK293T and CHODG-44 to obtain purified antigens with future applications in therapeutic vaccines against HPV-16 and HPV-18 associated tumors. The genes encoding the gDE7E6 proteins HPV-16 and HPV-18 and E7 HPV-16 were cloned into the pPIC9K vector, which were linearized by enzymatic digestion and used in the transformation of P. pastoris. Expression of the proteins was analyzed at 24, 48, 72 and 96 hours, however, the production of the proteins in the supernatant and in the cell lysate was not observed. In light of this finding, we initiated the expression of gDE7E6 proteins HPV-16 and HPV-18 in mammalian cells HEK293T and CHODG-44. The genetic sequences of gDE7E6 proteins HPV-16 and HPV-18 were cloned into the pNU1 expression vector and analyzed by enzymatic digestion. SDSPAGE and western blot analyzes demonstrated expression of gDE7E6 proteins HPV-16 and HPV-18 within 96 hours in HEK293T cells. In parallel, we performed stable transfection of plasmids containing gDE7E6 HPV-16 and HPV-18 sequences into CHODG44 cells. In order to increase the expression of the proteins in the mixed population of CHODG-44, we performed genomic amplification with methotrexate (MTX), and it was possible to observe an increase in protein expression, as a gradual increase in MTX concentrations. Therefore, attempts were made to isolate a clone producing gDE7E6 proteins HPV-16 and HPV-18 by limiting dilution and automated system, being possible to isolate one clone for each construct through a semisolid matrix, confirmed by western blot and flow cytometry. Despite observing protein expression in mammalian cell-based expression system, the yield obtained after nickel affinity purification was extremely low, which makes it difficult to obtain the antigens for vaccine purposes.

Abstract not available

Abstract not available